ELYM Key Statistics, Chart & Performance
The current stock price of ELYM is 5.11 USD. In the past month the price decreased by -29.42%. In the past year, price increased by 95.04%.
ELYM Latest News, Press Relases and Analysis
ELYM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About ELYM
Company Profile
Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wilmington, Delaware and currently employs 9 full-time employees. The company went IPO on 2021-08-10. The company is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company also focuses on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing TNT119, an anti-CD19 antibody designed for a range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. Its clinical-stage program, ETX-155, is an investigational, oral, neuroactive steroid NCE that is designed to act as a positive allosteric modulator (PAM) of the GABAA receptor (GABAAR). The GABAA PAM neuroactive steroid class has been clinically validated in depression and epilepsy. ETX-155 for use in multiple disorders of high unmet need, including major depressive disorder (MDD) and focal onset seizures (FOS).
Company Info
ELIEM THERAPEUTICS INC
2801 Centerville Road 1St Floor, Pmb #117
Wilmington DELAWARE US
CEO: Robert Azelby
Employees: 10
Phone: 18773543689
ELIEM THERAPEUTICS INC / ELYM FAQ
What does ELIEM THERAPEUTICS INC do?
Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wilmington, Delaware and currently employs 9 full-time employees. The company went IPO on 2021-08-10. The company is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company also focuses on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing TNT119, an anti-CD19 antibody designed for a range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. Its clinical-stage program, ETX-155, is an investigational, oral, neuroactive steroid NCE that is designed to act as a positive allosteric modulator (PAM) of the GABAA receptor (GABAAR). The GABAA PAM neuroactive steroid class has been clinically validated in depression and epilepsy. ETX-155 for use in multiple disorders of high unmet need, including major depressive disorder (MDD) and focal onset seizures (FOS).
What is the stock price of ELIEM THERAPEUTICS INC today?
The current stock price of ELYM is 5.11 USD. The price decreased by -0.97% in the last trading session.
Does ELIEM THERAPEUTICS INC pay dividends?
ELYM does not pay a dividend.
What is the ChartMill technical and fundamental rating of ELYM stock?
ELYM has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting ELYM stock to perform?
6 analysts have analysed ELYM and the average price target is 4.59 USD. This implies a price decrease of -10.18% is expected in the next year compared to the current price of 5.11.
Can you provide the number of employees for ELIEM THERAPEUTICS INC?
ELIEM THERAPEUTICS INC (ELYM) currently has 10 employees.
ELYM Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ELYM. When comparing the yearly performance of all stocks, ELYM is one of the better performing stocks in the market, outperforming 88.48% of all stocks.
ELYM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ELYM. While ELYM has a great health rating, there are worries on its profitability.
ELYM Financial Highlights
Over the last trailing twelve months ELYM reported a non-GAAP Earnings per Share(EPS) of -2.15. The EPS decreased by -27.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.4% | ||
| ROE | -28.88% | ||
| Debt/Equity | 0 |
ELYM Forecast & Estimates
6 analysts have analysed ELYM and the average price target is 4.59 USD. This implies a price decrease of -10.18% is expected in the next year compared to the current price of 5.11.